[{"innerBlocks":[],"name":"core\/freeform","postId":1921,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"The Department of Veterans Affairs and IBM have extended their public-private partnership for another year.

The agreement will enable VA oncologists to continue using IBM\u2019s Watson for Genomics for the identification of cancer-causing mutations and treatment options.

During the past two years, the VA\u2019s precision oncology program\u2014which primarily supports stage 4 cancer patients who have exhausted other treatment options\u2014has leveraged the Watson for Genomics artificial intelligence technology under the National Cancer Moonshot Initiative to provide care for more than 2,700 veterans. The extension of the partnership will run through at least June 2019.

\u201cVA is leading the nation to scale and spread the delivery of high quality precision oncology care, one veteran at a time,\u201d said Kyu Rhee, MD, chief health officer for IBM Watson Health. \u201cIt is incredibly challenging to read, understand and stay up-to-date with the breadth and depth of medical literature and link them to relevant mutations for personalized cancer treatments. This is where AI can play an important role in helping to scale precision oncology, as demonstrated in our work with VA, the largest integrated health system in the U.S.\u201d

Also See<\/b>: AI use in cancer treatment is in the early stages<\/a>

At a central \u201chub\u201d facility in Durham, N.C., a small group of VA oncologists and pathologists take tumor samples from patients nationwide and sequence the DNA, which they then use Watson for Genomics to help interpret the genomic data to identify mutations and potential treatment options.

According to the VA, it treats 3.5 percent of America\u2019s cancer patients\u2014more than any single healthcare organization group\u2014and more than one-third of the patients who have benefited from the VA\u2019s precision oncology program are veterans from rural areas.

\u201cOur mission with VA\u2019s precision oncology program is to bring the most advanced treatment opportunities to veterans, in hopes of giving our nation\u2019s heroes better treatments through these breakthroughs,\u201d said Acting VA Secretary Peter O\u2019Rourke. \u201cWe look forward to continuing this strategic partnership to assist VA in providing the best care for our veterans.\u201d","saveContent":"The Department of Veterans Affairs and IBM have extended their public-private partnership for another year.

The agreement will enable VA oncologists to continue using IBM\u2019s Watson for Genomics for the identification of cancer-causing mutations and treatment options.

During the past two years, the VA\u2019s precision oncology program\u2014which primarily supports stage 4 cancer patients who have exhausted other treatment options\u2014has leveraged the Watson for Genomics artificial intelligence technology under the National Cancer Moonshot Initiative to provide care for more than 2,700 veterans. The extension of the partnership will run through at least June 2019.

\u201cVA is leading the nation to scale and spread the delivery of high quality precision oncology care, one veteran at a time,\u201d said Kyu Rhee, MD, chief health officer for IBM Watson Health. \u201cIt is incredibly challenging to read, understand and stay up-to-date with the breadth and depth of medical literature and link them to relevant mutations for personalized cancer treatments. This is where AI can play an important role in helping to scale precision oncology, as demonstrated in our work with VA, the largest integrated health system in the U.S.\u201d

Also See<\/b>: AI use in cancer treatment is in the early stages<\/a>

At a central \u201chub\u201d facility in Durham, N.C., a small group of VA oncologists and pathologists take tumor samples from patients nationwide and sequence the DNA, which they then use Watson for Genomics to help interpret the genomic data to identify mutations and potential treatment options.

According to the VA, it treats 3.5 percent of America\u2019s cancer patients\u2014more than any single healthcare organization group\u2014and more than one-third of the patients who have benefited from the VA\u2019s precision oncology program are veterans from rural areas.

\u201cOur mission with VA\u2019s precision oncology program is to bring the most advanced treatment opportunities to veterans, in hopes of giving our nation\u2019s heroes better treatments through these breakthroughs,\u201d said Acting VA Secretary Peter O\u2019Rourke. \u201cWe look forward to continuing this strategic partnership to assist VA in providing the best care for our veterans.\u201d","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

VA extends cancer initiative with IBM to leverage Watson

More for you